Inovio stock news. Jan 12, 2024 · Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP. Read my analysis of INO stock. 10, 2023 8:47 AM ET Inovio Pharmaceuticals, Inc. Shares Out 25. 29% from the previous closing price of $0. The market assigns some value to the company. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Share your opinion and gain insight from other stock traders and investors. All. Common Stock (INO) Real-Time Quotes | Nasdaq. 5 million common shares outstanding and 247. INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. 4 days ago · 0. These targeted T cells are designed to seek out and kill HPV-6 and HPV-11 Feb 21, 2024 · Inovio Pharmaceuticals (INO) closed the last trading session at $8. is a clinical-stage biotechnology company. 09, 2022 Inovio Pharmaceuticals GAAP EPS of -$0. Oct 10, 2023 · Oct. Volume today is high. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7. 10 per share. $315. Nov 8, 2022 · As of September 30, 2022, INOVIO had 249. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA Aug 9, 2023 · Shares Outstanding: As of June 30, 2023, INOVIO had 268. , June 23, 2023 (GLOBE NEWSWIRE) - INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA: UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. 994. We use proprietary technology to design DNA plasmids —small circular DNA molecules that work like software that the body’s cells can download to learn how to produce specific proteins to target The latest Inovio Pharmaceuticals stock prices, stock quotes, news, and INO history to help you invest and trade smarter. You have to travel deep into the wayback machine to 02/2009 to find intraday Inovio trading below $1. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Find the latest news headlines from Inovio Pharmaceuticals, Inc. stock news by MarketWatch. May 14, 2024 · InvestorPlace - Stock Market News, Stock Advice & Trading Tips. The decision follows INOVIO's comprehensive review of its portfolio May 26, 2024 · Inovio Pharmaceuticals, Inc. Oct 19, 2023 · Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA. 3. 23, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO ), a biotechnology company focused on developing and commercializing Sep 7, 2023 · INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U. 8 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. $ Market cap P/E ratio $ Price 1d change 52-week range. Aug 26, 2021 · INOVIO's global Phase 3 efficacy trial receives authorization to proceed from Brazil; other countries to follow INOVIO to conduct INNOVATE Phase 3 efficacy trial with partner Advaccine in areas of world in need of COVID-19 vaccines INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases Nov 9, 2021 · FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U. 36, the closing price of INOVIO's common stock on the Grant Date. S. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA Jan 23, 2024 · INOVIO Pharmaceuticals, Inc. Get the latest Inovio Pharmaceuticals, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. 57. 10, 2023, 08:26 AM. The stock option will vest and become exercisable with respect to one-fourth of the Shares of Inovio Pharmaceuticals Inc. stock information by Barron's. 7 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. Food and Drug Administration (FDA) provided authorization to proceed for INOVIO's INNOVATE Phase 3 INOVIO is a clinical-stage biotechnology company focused on developing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA. Find the latest Inovio Pharmaceuticals, Inc. 6% from the stock's current price. 39M. May 10, 2023 · Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatment New combined safety and immunological data showing tolerability and durable immune response presented at ABEA/COSM Announced positive data Jan 24, 2024 · Inovio Pharmaceuticals (NASDAQ:INO) stock is taking a beating on Wednesday as the biotechnology company prepares for a reverse stock split. 15 beats by $0. Inovio Pharmaceuticals Inc (INO. Inovio Pharmaceuticals (NASDAQ: INO) just reported results for the first quarter of 2024. 83% to $9. (INO) released Loss for fourth quarter that decreased from last year. Nov 9, 2023 · Shares Outstanding: As of September 30, 2023, INOVIO had 269. 6 million common shares outstanding on a fully diluted basis, after giving effect to the Feb 21, 2024 · INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter and year-end 2023 financial results will be released after the market close on March 6, 2024. Dividend Yield -. View Inovio Pharmaceuticals, Inc. Nov 9, 2021 · INO stock was up 5. 2:20-cv-01962-GJP NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF Mar 28, 2024 · Inovio Pharmaceuticals (INO) Company Description: Inovio Pharmaceuticals, Inc. The grant includes restricted stock units (RSUs) covering 3,750 shares of common stock and an option to purchase 5,833 shares of common stock. (INO) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. May 13, 2024 · INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants. Read more here. Inovio leverages its optimized plasmid design and delivery technology to develop DNA medicines to Nov 9, 2022 · Inovio Pharmaceuticals reported quarterly losses of 15 cents per share which beat the analyst consensus estimate of a loss of 30 cents. 5 million and $144. Their INO share price targets range from $20. 0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. On May 13 See Inovio Pharmaceuticals, Inc. May 11, 2022 9:28 AM ET Inovio Pharmaceuticals, Inc. hapabapa. 82 Monday, on what proved to be an all-around grim trading session for the stock market, with the Seeking Alpha. 74 as of 1:32 PM on Friday, Jan 5, a gain of $0. 0 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible debt. MX) stock news and headlines to help you in your trading and investing decisions. Common Stock (INO) at Nasdaq. INOVIO reported See the latest Inovio Pharmaceuticals Inc stock price (INO:XNAS), related news, valuation, dividends and more to help you make your investing decisions. INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan"). May 10, 2024 · Inovio Pharmaceuticals, Inc. Get the latest Inovio Pharmaceuticals Inc (GBM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (INO. 91M. 13, the closing price of INOVIO's common stock on the Grant Date. g9GOWCcEEI0L8xSTstSATXzIDa-XZyrup_v5Du46Evb-574lEX8G3AnmJA May 10, 2022 · As of March 31, 2022, the Company had 226. , Jan. Conversation. There’s more stock market news worth looking into below! InvestorPlace has all the latest stock market coverage that traders need today. So far 9,757,846 shares have traded compared to average volume of 2,818,897 shares. You have to Jan 3, 2024 · Inovio Pharmaceuticals (INO) Company Description: Inovio Pharmaceuticals, Inc. Find out all the key statistics for Inovio Pharmaceuticals, Inc. PLYMOUTH MEETING, Pa. We would like to show you a description here but the site won’t allow us. 10 Day Average Volume 0. Mar 7, 2024 · Inovio Pharmaceuticals (INO) Company Description: Inovio Pharmaceuticals, Inc. In the analyst's view, INO-5401 could be a "potential breakthrough" drug for treating patients with glioblastoma, a cancer Complete Inovio Pharmaceuticals Inc. Jan 23, 2024 · INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases Mar 1, 2023 · As of December 31, 2022, INOVIO had 253. May 11, 2022 · Energy Stock News; Tech Stock News; IPO News; Market Data Collapse menu. If you experience any issues with this process, please contact us for further assistance. INOVIO Reports Inducement Grants Under Inducement Plan. However, it is assigning a heavy discount when one considers that Jan 3, 2024 · About INO-3107 INO-3107 is designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 proteins. Jul 19, 2022 · Changes expected to reduce operational expenses and extend the company's cash runway into third quarter of 2024 Improving cost structure will allow company to focus on strategic priorities, including heterologous boost strategy for COVID-19 vaccine candidate and HPV programs INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect Find the latest Inovio Pharmaceuticals, Inc. News Sep 7, 2023 · INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases Inovio Pharmaceuticals stock rises on Q3 profit beat, raised cash runway guidance SA News Wed, Nov. This suggests a possible upside of 597. Food and Drug Administration (FDA) that Nov 1, 2023 · The stock option has an exercise price of $0. 57 and $0. (INO) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The stock has traded between $0. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis Oct 27, 2022 · INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Jan 23, 2024, 08:00 ET. GuruFocus. Market Cap 285. (INO) stock price, news, historical charts, analyst ratings and financial information from WSJ. 5 days ago · The latest Inovio Pharmaceuticals stock prices, stock quotes, news, and INO history to help you invest and trade smarter. 81%. (INO) Stock By: Dulan Lokuwithana, SA News Editor 13 Comments. View the latest Inovio Pharmaceuticals Inc. (RTTNews) - Biotechnology company Inovio Pharmaceuticals, Inc. The grant, approved by INOVIO's Compensation Committee, involves options to purchase 1,666 shares at $10. 13 per share, the closing price on May 31, 2024. 018M. INO has a High Technical Rating by Nasdaq Dorsey Wright. The company was founded by David B. The company's bottom line came in at -$25 million, or -$1. Following the release, INOVIO will host a live conference call and Find the latest Inovio Pharmaceuticals, Inc. Jan 8, 2024 · At INOVIO, we promise to treat your data with respect and will not share your information with any third party. 4 days ago · The stock option has an exercise price of $10. 52 Week Low Date 11/10/23. 6% as of Tuesday afternoon. Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. (INO) stock discussion in Yahoo Finance's forum. 15M At INOVIO, we promise to treat your data with respect and will not share your information with any third party. Discover why technical analysis Apr 4, 2023 · Inovio's recent share drop below $1. 17, gaining 17. On Tuesday, Inovio Pharmaceuticals (INO) announced that Thermo Fisher Scientific had signed a letter of intent to Oct 11, 2023 · Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher again on Wednesday after surging more than 40% on Tuesday after the FDA said it can use data from the completed Phase 1 Aug 1, 2023 · Inovio Pharmaceuticals (INO) added ~3% pre-market Tuesday after announcing plans to lay off about 30% of staff as part of a restructuring initiative. View real-time stock prices and stock quotes for a full financial overview. May 13, 2024 · INOVIO (NASDAQ:INO), a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, announced an equity grant under its 2022 Inducement Plan. Jan 4, 2024 · INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. More About Inovio Feb 6, 2024 · INO-3107 takes center stage in Inovio's pipeline with plans for a near term BLA filing, benefiting from ample liquidity until Q2, 2025. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section. 1 million common shares outstanding and 271. DNA medicines company Inovio Pharmaceuticals (NASDAQ: INO | Complete Inovio Pharmaceuticals Inc. We use proprietary technology to design DNA plasmids —small circular DNA molecules that work like software that the body’s cells can download to learn how to produce specific proteins to target Plymouth Meeting, Pa. The stock options will vest and become exercisable with respect to one-fourth of the 3 days ago · May 31, 2024, 4:00 PM EDT - Market closed. (INO), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Mar 6, 2024 · (RTTNews) - Inovio Pharmaceuticals Inc. tITUYV00R-hjn22l_aTONQT_Pf3fLU23y7TLfJdWcKU. 1 million common shares outstanding and 290. . YTD % Change 79. 00. com. rose 2. 5 million common shares outstanding and 268. 8 Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company also reported quarterly sales of $9. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA Jan 12, 2024 · Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP. May 13, 2024 · Strengthened balance sheet with an offering of common stock and pre-funded warrants in April 2024; net proceeds from the offering, after deducting underwriting discounts and commissions and Jun 27, 2023 · One ought not dismiss the significance of Inovio's market cap of ~$113 million. 3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set Apr 15, 2024 · PLYMOUTH MEETING, Pa. Menu icon A vertical stack of three evenly spaced horizontal lines. 74. 68% ( 1D) News. 1mo. (INO) stock quote, history, news and other vital information to help you with your stock trading and investing. 67 in the next year. Go here to track Inovio Pharmaceuticals stock price in real-time ahead of earnings. 00 to $144. (INO) stock news and headlines to help you in your trading and investing decisions. INO | Complete Inovio Pharmaceuticals Inc. The company’s shares will undergo a 1-for-12 reverse May 24, 2024 · A high-level overview of Inovio Pharmaceuticals, Inc. Earnings Date : May 13, 2024. Dividend -. 15, revenue of $9. NYSE): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Inovio Pharmaceuticals Inc | Nyse: INO | Nyse 2945614f7e0718d5cbf5c. 8 million for the quarter and year ended December 31, 2023, respectively, compared to $56. INO Competitors. Jan 25, 2024 · Inovio Pharmaceuticals, Inc. Dec 14, 2021 · INOVIO completes enrollment of REVEAL2 Long-term data favorable from REVEAL1 INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous Stock analysis for Inovio Pharmaceuticals Inc (INO:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. (INO) Stock By: Dulan Lokuwithana, SA News Editor 5 Comments. INO stock quote prices, financial information, real-time forecasts, and company news from Feb 2, 2024 · INOVIO (NASDAQ:INO) has announced an equity grant to a newly hired employee under its 2022 Inducement Plan. Inovio stock surges to seven-month high. 77 so far today. , April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. DERIVATIVE LITIGATION Lead Case No. (INO) stock. 17, or 29. Beta 1. Mar 6, 2024 · Total Operating Expenses: Total operating expenses were $27. May 26, 2024 · Get Inovio Pharmaceuticals Inc (INO. PR Newswire Apr 15, 2024 10:39pm. The RSUs will vest over a three-year period, with one-third of the shares vesting on each of the first, second, and third anniversaries of the Get the latest Inovio Pharmaceuticals, Inc. 1 million and $277. Shares of Inovio Pharmaceuticals (NASDAQ:INO) climbed ~29% on Friday to reach the highest level in more than seven months on above Judge Pappert said that Inovio agreed to pay an award of at least $44 million, $30 million of which is to be paid in cash, with the remainder paid in either 7 million shares of Inovio common stock Sep 10, 2021 · Get the latest Inovio Pharmaceuticals Inc. (Coherus, NASDAQ: CHRS) to evaluate the combination of INO-3112 and LOQTORZI™ (toripalimab-tpzi) as a Sep 10, 2020 · This week, one of the key players in the COVID-19 vaccine race took a leap forward. On average, they anticipate the company's share price to reach $70. Press Releases. Videos. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Inovio Pharmaceuticals reported earnings Jan 5, 2024 · Inovio Pharmaceuticals Inc (INO) stock is trading at $0. is a late-stage biotechnology company, which engages in the discovery, development, and commercialization of DNA Nov 9, 2021 · INO stock was up 5. View real-time INO stock price and news, along with industry-best analysis. Jan 5, 2024 · Inovio Pharmaceuticals (INO) stock surges to reach a seven month high on the back of a clinical trial pact and a plans to file a marketing application. 7 million common shares outstanding and 290. 15 million Nov 9, 2021 · INO stock was up 5. INO stock quote prices, financial information, real-time forecasts, and company news from 4 days ago · 4 brokers have issued 12 month price targets for Inovio Pharmaceuticals' stock. 00 is a new and unprecedented development. 41B. INOVIO's balance Feb 12, 2021 · Finally, Singh sees INO-5401 as worth perhaps $5 a share to Inovio stock. (INO) announced Tuesday that it has received feedback from the U. May 12, 2024 · Analysts on Wall Street predict Inovio Pharmaceuticals will release losses per share of $0. nr ea tr er ll rq ft yo dd ys